Molecular Roadmap of COVID‐19: From Viral Entry to Therapeutic Targets
Chemistry & Biodiversity · 2026-01 · 23 (1)
DOI: 10.1002/cbdv.202501534 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemistry & Biodiversity, online erschienen am 30.10.2025. Verfasst von Afeez Adekunle Ishola und 2 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Therapeutics Branch (DTB) of the National Cancer Institute (NCI), National Institute of Health (NIH), Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, COVID-19 Drug Treatment, Virus Internalization. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Although the global emergency of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has subsided, the pandemic is not over, making the development of effective therapeutics crucial to reduce mortality and restore patient health. Identifying host molecular pathways targeted by the virus is essential for drug discovery, whether through repurposing existing drugs or developing new ones. This review examines the molecular mechanisms of SARS‐CoV‐2 infection, including signaling pathways, therapeutic targets, viral entry and replication strategies, and associated clinical features. It also discusses current global infection and mortality trends, clinical management, and prospects for drug development. Data were sourced from major scientific databases. Given the virus's high mutation rate and ongoing impact, multidisciplinary collaboration is needed. Plant‐derived compounds and herbal medicines show promise as potential antiviral interventions against coronavirus disease 2019 (COVID‐19). The information and data on COVID‐19 were collated from various resources and literature databases such as PubMed, Science Direct, Wiley, Springer, Taylor and Francis, Scopus, Inflibnet, Google, and Google Scholar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Developmental Therapeutics Branch (DTB) of the National Cancer Institute (NCI), National Institute of Health (NIH), Bethesda, Maryland, USA.
- Department of Biotechnology, School of Applied Science, Lincoln University College, Petaling Jaya, Selangor, Malaysia.
- Mimia Skincare Sdn. Bhd., Kuala Lumpur, Malaysia.
ORCID-Profile: Idris Adewale Ahmed
Zitieren
APA
Ishola, A. A., Ahmed, I. A., & Mikail, M. A. (2026). Molecular Roadmap of COVID‐19: From Viral Entry to Therapeutic Targets. Chemistry & Biodiversity, 23(1). https://doi.org/10.1002/cbdv.202501534
Vancouver
Ishola AA, Ahmed IA, Mikail MA. Molecular Roadmap of COVID‐19: From Viral Entry to Therapeutic Targets. Chemistry & Biodiversity. 2026;23(1). doi:10.1002/cbdv.202501534
BibTeX
@article{Ishola2026,
author = {Ishola, Afeez Adekunle and Ahmed, Idris Adewale and Mikail, Maryam Abimbola},
title = {Molecular Roadmap of COVID‐19: From Viral Entry to Therapeutic Targets},
journal = {Chemistry & Biodiversity},
year = {2026},
volume = {23},
number = {1},
doi = {10.1002/cbdv.202501534}
}
EUVIMED